Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Sponsor: Concert Pharmaceuticals
A PHASE2 clinical study on Alopecia Areata, this trial is completed. The trial is conducted by Concert Pharmaceuticals and has accumulated 12 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2020 — Dec 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Apr 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Concert Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .